Effect of metformin on prostate cancer outcomes after radical prostatectomy.

ABSTRACT:

Objective

Recent studies have shown a relative risk reduction in the incidence of prostate cancer in patients taking metformin. However, there are conflicting findings on the effect of metformin on established cases of prostate cancer. In this study we evaluated the effect of metformin on survival and pathologic outcomes in established prostate cancer.

Materials and methods

We retrospectively identified 12,052 patients who underwent radical prostatectomy between 1997 and 2010 at Mayo Clinic. Among these, 885 (7.3%) were diabetics, including 323 taking and 562 not taking metformin. Kaplan-Meier method was utilized to calculate rates of biochemical recurrence (BCR), systemic progression (SP), and all-cause mortality (ACM). Cox models were used to estimate the metformin hazard

SUBMITTER: Kaushik D 

PROVIDER: S-EPMC4006350 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature